ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires théa - hexamidine diisetionate 10 mg/10 ml - eye drops, solution - 1 mg/ml - hexamidine diisetionate 1 mg/ml - hexamidine

タンザニア - 英語 - Tanzania Medicinces & Medical Devices Authority

beijing holley cotec pharmaceuticals co., ltd, china - gentamycin sulfate - solution for injection - 80mg/2ml

日本 - 英語 - すりの適正使用協議会 RAD-AR Council, Japan

alfresa pharma corporation - benfotiamine; pyridoxine hydrochloride; cyanocobalamin - pale reddish powder

日本 - 英語 - すりの適正使用協議会 RAD-AR Council, Japan

alfresa pharma corporation - thiamine disulfide phosphate; pyridoxine hydrochloride; cyanocobalamin - injection

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - etanercept, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; glycine; sucrose; sodium citrate dihydrate; monobasic sodium phosphate dihydrate - nepexto is indicated for the treatment of:,adults,rheumatoid arthritis,active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). nepexto can be used in combination with methotrexate.,severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.,psoriatic arthritis,the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. etanercept has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.,plaque psoriasis,adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.,ankylosing spondylitis,the signs and symptoms of active ankylosing spondylitis in adults.,non-radiographic axial spondyloarthritis,treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids.,* active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of >= 4.,children and adolescents,children and adolescents weighing less than 62.5 kg should not receive nepexto. these patients should be accurately dosed on a mg/kg basis with other etanercept products.,juvenile idiopathic arthritis,active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more dmards.,active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate.,active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy.,active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate.,etanercept has not been studied in children aged less than 2 years.,paediatric plaque psoriasis,chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant psoriasis area and severity index (pasi) response is not achieved.

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - abamectin - topical solution/suspension - abamectin anthelmintic active 10.0 g/l - parasiticides - cattle - beef | dairy cattle | bovine | breeders | bullocks | bulls | calves | cows | dairy cow | feedlot cattle | growers | hei - barber's pole worm - haemonchus placei | cattle biting louse | cattle tick | cooperia oncophora | cooperia punctata | hookworm - bunostomum phlebotomum | intestinal threadworm - s. papillosus | lungworm - dictyocaulus viviparus | nodule worm - oesophagostomum radiatum | shortnosed cattle louse | small brown stomach worm - o. ostertagi | small brown stomach worm-ostertagia spp. | stomach hair worm | sucking lice - linognathus vituli | thin necked intestinal worm-n. spathiger | tubercle-bearing louse | whipworm - trichuris spp. | cattlebiting louse | damalinia bovis (old name) | including inhibited stages | large lungworm | little blue sucking louse | short nosed sucking louse | small intestinal worm | teladorsagia | thin necked intestinal worm-ad

スペイン - 英語 - HMA (Heads of Medicines Agencies)

boehringer ingelheim espaÑa - pimobendan 10 mg - capsule, hard - dogs non food - pimobendane

ポルトガル - 英語 - HMA (Heads of Medicines Agencies)

boehringer ingelheim espaÑa - pimobendan 10 mg - capsule, hard - dogs non food - pimobendane

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 5.0 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral capsule - pimobendan pyridazinone active 1.25 mg/cp - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency